Maximum Tolerated Dose, Schedule for Lenalidomide for Leukemia, Lymphoma Identified

Share this content:
Maximum tolerated dose and schedule for lenalidomide treatment in adult T-cell leukemia-lymphoma may be 25 mg/day given continuously.
Maximum tolerated dose and schedule for lenalidomide treatment in adult T-cell leukemia-lymphoma may be 25 mg/day given continuously.

The maximum tolerated dose and schedule for lenalidomide treatment in patients with previously treated aggressive, adult T-cell leukemia-lymphoma may be 25 mg/day given continuously, according to a Japanese population study published in The Lancet Haematology.1

Researchers led by Michinori Ogura, MD, of the Nagoya Daini Red  Cross Hospital in Aichi, Japan, conducted a phase 1 study of 14 patients with documented diagnosis of aggressive adult T-cell leukemia-lymphoma or other peripheral T-cell lymphoma subtypes from 6 centers in Japan who were 20 years or older with Eastern Cooperative Oncology Group performance status of 0 to 2.

Primary endpoint was the identification of a maximum tolerated dose of lenalidomide, with analyses performed per protocol for efficacy and in the intent-to-treat population for safety.

Among 13 patients who were assessable for receiving lenalidomide, dose-limiting toxic effects were reported in 3 patients during cycle 1, 1 grade 3 QT prolongation on electrocardiogram, 1 grade 3 fatigue, and 1 grade 4 thrombocytopenia.

RELATED: VEPEMB Compared With ABVD for Older Patients With Hodgkin Lymphoma

Maximum tolerated dose was identified as lenalidomide 25 mg/day given continuously, with the most common grade 3 or worse adverse events being neutropenia, lymphopenia, and thrombocytopenia. Serious adverse events were found to have occurred in 8 patients.

Reference

  1. Ogura M, Imaizumi Y, Uike N, et al. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study [published online ahead of print February 11, 2016]. Lancet Haematol. doi: 10.1016/S2352-3026(15)00284-7.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters